TransMedics Group Inc.
TMDX | NASDAQ
$88.19
+$0.90 (+1.03%)
Sep 22, 2026, 12:26 PM ET · Market open
Company Profile
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Waleed H. Hassanein | Founder, President, Chief Executive Officer & Director |
| Gerardo Hernandez | Chief Financial Officer & Treasurer |
| Anil Ranganath | Advisor |
| Matthew Forsyth | Senior Vice President, General Counsel & Corporate Secretary |
| Miriam C. Provost | Vice President of Global Regulatory Affairs |
| Nicholas Corcoran | Senior Vice President of Supply Chain & Operations |
| Tamer I. Khayal | Senior Vice President of International |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 17, 2026 | 4 | Filing |
| Aug 04, 2026 | 10-Q | Quarterly Report |
| Aug 04, 2026 | 8-K | Current Report |
| Jul 14, 2026 | 4 | Filing |
| Jul 14, 2026 | 4 | Filing |
| Jul 14, 2026 | 4 | Filing |
| Jun 17, 2026 | 4 | Filing |
| May 29, 2026 | SD | Filing |
| May 22, 2026 | 4 | Filing |
| May 22, 2026 | 4 | Filing |
TransMedics Group Inc.
| Country | United States |
| IPO Date | May 1, 2019 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 898 |
| CEO | Waleed H. Hassanein |
Contact Details
200 Minuteman Road Andover,
Massachusetts 01810 United States
Stock Details
| Ticker Symbol | TMDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001756262 |
| CUSIP Number | 89377M109 |
| ISIN Number | US89377M1099 |
| SIC Code | 3845 |
Recent News
- 6 days ago / defenseworld.netTransMedics Group (NASDAQ:TMDX) Shares Up 4.5% After Insider Buying Activity
- 8 days ago / seekingalpha.comTransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 8 days ago / gurufocus.comTransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
- 12 days ago / prnewswire.comTransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
- 15 days ago / prnewswire.comDid TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
- 19 days ago / gurufocus.comTransMedics Group Inc (TMDX) Shares Surge 3.2% -- What GF Score of 69 Tells Investors
- 19 days ago / zacks.comIs TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
- 19 days ago / zacks.comWhy Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?
- 22 days ago / gurufocus.comRosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
- 22 days ago / prnewswire.comTransMedics to Present at Upcoming September Investor Conferences
Add to Watchlist
Select watchlists to add or remove TMDX